These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17167386)

  • 1. Role of natriuretic peptides in heart failure patients with special reference to those on cardiac resynchronization therapy.
    Ricciardi G; Pieragnoli P; Colella A; Giaccardi M; Padeletti L; Abbate R; Gensini GF; Michelucci A
    Minerva Cardioangiol; 2006 Dec; 54(6):743-52. PubMed ID: 17167386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony.
    Fruhwald FM; Fahrleitner-Pammer A; Berger R; Leyva F; Freemantle N; Erdmann E; Gras D; Kappenberger L; Tavazzi L; Daubert JC; Cleland JG
    Eur Heart J; 2007 Jul; 28(13):1592-7. PubMed ID: 17298973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial.
    Cleland J; Freemantle N; Ghio S; Fruhwald F; Shankar A; Marijanowski M; Verboven Y; Tavazzi L
    J Am Coll Cardiol; 2008 Aug; 52(6):438-45. PubMed ID: 18672164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial.
    Daubert C; Gold MR; Abraham WT; Ghio S; Hassager C; Goode G; Szili-Török T; Linde C;
    J Am Coll Cardiol; 2009 Nov; 54(20):1837-46. PubMed ID: 19800193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is implantable defibrillator indicated in all patients on cardiac resynchronization therapy?
    Pieragnoli P; Ricciardi G; Colella A; Musilli N; Porciani MC; Giaccardi M; Padeletti L; Michelucci A
    Minerva Cardioangiol; 2006 Dec; 54(6):735-41. PubMed ID: 17167385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility, safety, and mid-term efficacy of cardiac resynchronization therapy in patients with severe heart failure and ventricular conduction delay: Chulalongkorn experience.
    Sunsaneewitayakul B; Sitthisook S; Sangwatanaroj S; Prechawat S; Songmuang SB
    J Med Assoc Thai; 2007 Jul; 90(7):1458-66. PubMed ID: 17710992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac resynchronization therapy in patients with end-stage inotrope-dependent class IV heart failure.
    Herweg B; Ilercil A; Cutro R; Dewhurst R; Krishnan S; Weston M; Barold SS
    Am J Cardiol; 2007 Jul; 100(1):90-3. PubMed ID: 17599447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac resynchronization therapy for the treatment of heart failure.
    Nayar V; Pugh PJ
    Expert Rev Cardiovasc Ther; 2010 Feb; 8(2):229-39. PubMed ID: 20136609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of upgrading from right ventricular pacing to cardiac resynchronization therapy in patients with heart failure.
    Foley PW; Muhyaldeen SA; Chalil S; Smith RE; Sanderson JE; Leyva F
    Europace; 2009 Apr; 11(4):495-501. PubMed ID: 19307283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BNP/NT-proBNP and cardiac pacing: a review.
    Wang RX; Guo T; Li XR
    Pacing Clin Electrophysiol; 2009 Jun; 32(6):794-9. PubMed ID: 19545345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diastolic filling pattern and left ventricular diameter predict response and prognosis after cardiac resynchronisation therapy.
    Gradaus R; Stuckenborg V; Löher A; Köbe J; Reinke F; Gunia S; Vahlhaus C; Breithardt G; Bruch C
    Heart; 2008 Aug; 94(8):1026-31. PubMed ID: 17984216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac resynchronization therapy in heart failure patients: an update.
    Jeevanantham V; Daubert JP; Zareba W
    Cardiol J; 2009; 16(3):197-209. PubMed ID: 19437393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natriuretic peptide testing in clinical medicine.
    Rehman SU; Januzzi JL
    Cardiol Rev; 2008; 16(5):240-9. PubMed ID: 18708825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute and chronic effects of cardiac resynchronization in patients developing heart failure with long-term pacemaker therapy for acquired complete atrioventricular block.
    Shimano M; Tsuji Y; Yoshida Y; Inden Y; Tsuboi N; Itoh T; Suzuki H; Muramatsu T; Okada T; Harata S; Yamada T; Hirayama H; Nattel S; Murohara T
    Europace; 2007 Oct; 9(10):869-74. PubMed ID: 17557768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program.
    Mullens W; Grimm RA; Verga T; Dresing T; Starling RC; Wilkoff BL; Tang WH
    J Am Coll Cardiol; 2009 Mar; 53(9):765-73. PubMed ID: 19245967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of natriuretic peptides at the point of care in the emergency and ambulatory setting: current status and future perspectives.
    Bingisser R; Cairns CB; Christ M; Collinson P; Hausfater P; Lindahl B; Mair J; Price C; Venge P
    Am Heart J; 2013 Oct; 166(4):614-621.e1. PubMed ID: 24093839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanical dyssynchrony in congestive heart failure: diagnostic and therapeutic implications.
    Nagueh SF
    J Am Coll Cardiol; 2008 Jan; 51(1):18-22. PubMed ID: 18174031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin.
    Francia P; Salvati A; Balla C; De Paolis P; Pagannone E; Borro M; Gentile G; Simmaco M; De Biase L; Volpe M
    Eur J Heart Fail; 2007 Mar; 9(3):306-9. PubMed ID: 16891152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis.
    Maisel AS; Peacock WF; McMullin N; Jessie R; Fonarow GC; Wynne J; Mills RM
    J Am Coll Cardiol; 2008 Aug; 52(7):534-40. PubMed ID: 18687247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The benefits of biventricular pacing in heart failure patients with narrow QRS, NYHA class II and right ventricular pacing.
    Ng K; Kedia N; Martin D; Tchou P; Natale A; Wilkoff B; Starling R; Grimm RA
    Pacing Clin Electrophysiol; 2007 Feb; 30(2):193-8. PubMed ID: 17338715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.